

GALECTIN THERAPEUTICS INC
Form 8-K
May 27, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 21, 2015

GALECTIN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)

Nevada
(State or Other Jurisdiction

001-31791
(Commission

04-3562325
(IRS Employer

of Incorporation)

File Number)

Identification No.)

4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 8-K

NORCROSS, GA 30071

(Address of principal executive office) (zip code)

Registrant's telephone number, including area code: (678) 620-3186

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 5 Corporate Governance and Management

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the 2015 Annual Meeting of Stockholders held on May 21, 2015, the stockholders of Galectin Therapeutics Inc. (Galectin or the Company) re-elected each of the Company s directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified. The stockholders also re-approved the material terms of the performance goals under the Company s Amended and Restated 2009 Incentive Compensation Plan and ratified the selection of McGladrey LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2015.

The final results of the voting on each matter of business at the 2015 Annual Meeting are as follows:

Election of Directors

| Name | Votes For | Votes Withheld | Broker Non-Votes |
|-------------------------------|-----------|----------------|------------------|
| Gilbert F. Amelio, Ph.D. | 5,169,682 | 416,629 | 10,999,123 |
| Kevin D. Freeman | 5,428,885 | 157,426 | 10,999,123 |
| Arthur R. Greenberg | 5,370,864 | 215,447 | 10,999,123 |
| John Mauldin | 4,305,569 | 1,280,742 | 10,999,123 |
| Gilbert S. Omenn, M.D., Ph.D. | 5,419,943 | 166,368 | 10,999,123 |
| Steven Prelack | 5,408,812 | 177,499 | 10,999,123 |
| Marc Rubin, M.D. | 5,424,577 | 161,734 | 10,999,123 |
| Peter G. Traber, M.D. | 5,373,392 | 212,919 | 10,999,123 |

Re-approval of the material terms of the performance goals under the Company s Amended and Restated 2009 Incentive Compensation Plan

| Votes For | Votes Against | Votes Abstain | Broker Non-Votes |
|-----------|---------------|---------------|------------------|
| 5,038,600 | 500,891 | 46,820 | 10,999,123 |

Ratification of the selection of McGladrey LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2015

| Votes For | Votes Against | Votes Abstain |
|------------|---------------|---------------|
| 16,345,497 | 142,159 | 97,778 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Galectin Therapeutics Inc.

Date: May 27, 2014

By: /s/ Jack W. Callicutt
Jack W. Callicutt
Chief Financial Officer